UNSPSC 51343801: Abacavir/lamivudine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class AM800. This VA Drug Class (AM800) classifies this compound as belonging to the group ANTIVIRALS.

The first component of this combination drug is a reverse transcriptase inhibitor with the molecular formula C14H18N6O, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier WR2TIP26VS, chemically known as 2-cyclopentene-1-methanol, 4-(2-amino-6-(cyclopropylamino)-9h-purin-9-yl)-, (1s-cis)- but more generally known as abacavir, which bears U.S. National Institutes of Health Compound Identifier 65140. Abacavir most often appears in forms succinate and sulfate, and is sometimes combined with lamivudine and zidovudine.

UNSPSC 51343801 Abacavir/lamivudine is a Commodity code that nominally designates a specific antiretroviral pharmaceutical product, but recent state and local opportunities show the code receiving minimal relevant activity. The three opportunities posted in the most recent window (January–June 2026) involve general medical and first aid supplies, naloxone and drug deactivation systems, direct-to-manufacturer prescription programs, and multi-source generic pharmaceuticals and OTC products — none of which target abacavir/lamivudine or other branded antiretroviral therapies by name. The mismatch between the code's nominal scope (a single fixed-dose combination HIV medication) and the actual solicitations suggests that state and local procurement systems may be applying this code to broader pharmaceutical purchasing categories, or that the code sees insufficient volume to generate dedicated opportunities.

The issuing bodies in the recent window span a single county health department (Seminole County, Florida), a city fire department (City of Tampa), a state HHS agency (Texas Health and Human Services Commission), and a multistate cooperative purchasing alliance (Minnesota Multistate Cooperative Purchasing Alliance serving multiple jurisdictions including Oregon). Geographic activity appears concentrated in Florida, Texas, and Minnesota, with no sustained pattern of repeat buyers under this specific code. The solicitations include an IFB for naloxone and drug deactivation systems (Seminole County, July 2026), an RFI for direct-to-manufacturer prescription programs (Texas HHS, April 2026), an IFB for medical and first aid supplies with Small Local Business Enterprise set-asides and a $700,000 estimated value (City of Tampa, March 2026), and an RFP for generic multi-source pharmaceuticals and OTC products through the Minnesota cooperative (March 2026). Activity does not indicate a market with depth sufficient to support a focused business-development strategy around this specific commodity code.